December 21, 2021
Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate
— Post-hoc, interim analysis published in Circulation: Heart Failure evaluated patients who received continuous treatment with VYNDAQEL/VYNDAMAX compared to those…